Congestive Heart Failure Drugs Market size was valued at US$ 7.62 Bn in 2022 and the total revenue is expected to grow at 12.8 % through 2022 to 2029, reaching nearly US$ 17.71 Bn.Congestive Heart Failure Drugs Market Overview:
Certain medical condition such as narrowing arteries of heart or High blood pressure gradually makes the heart too weak and not able to pump the blood continuously causes Heart attack or Heart Failure. Heart failure drugs are work in various ways like in case of heart attack such as ACE inhibitor prevent the formation angiotensin which causes blood vessel to constrict. Constrict blood vessel causes pressure on the wall of arteries and this lead to Heart failure and Heart Attack. ACE inhibitor helps to prevent the formation of angiotensin and relax the blood flow in the vessel. Increasing geriatric population and changing and unhealthy lifestyle globally, are the factors for driving the growth of Congestive Heart Failure Drug Market.Congestive Heart Failure Drugs Market Snapshot
To know about the Research Methodology :- Request Free Sample Report
Congestive Heart Failure Drugs Market Dynamics:
Approval of new drug from Food and Drug Administration is expected to grow the market of congestive heart failure. Urbanization with changing life style such as excessive alcohol consumption, Smoking and unhealthy diet causes the heart problem which propelling the growth of Congestive Heart Failure Drug. Rising cardio vascular disorder, the alarmin surge in cardiac ailments is estimated to create abundant opportunities for the heart failure drug market size development during forecast period. Increasing geriatric population with the unhealthy lifestyles and junk food drive the market. The drug used for the treatment of heart condition either increase the supply of oxygen to the heart or better the pumping capacity of the heart. Hypertension is the another medical condition that contribute to the increase the intake of drugs. The worldwide cardiovascular disease medications market is expected to grow rapidly during the forecast period in the coming years due to a large increase in drug uptake. The COVID-19 causes pneumonia, severe and acute respiratory problems, multiple organ failure, and death in the most severe instances. COVID-19 is more common in the elderly population. During the pandemic, the global market for cardiovascular disease medications grew rapidly. When compared to conventional calcium channel blockers, beta blockers, and diuretics, the demand for hypertension medications like Tracleer and Letairis is low. The worldwide cardiovascular disease medications market is expected to grow rapidly during the forecast period.Congestive Heart Failure Drugs Market Segment Analysis: The Congestive Heart Failure Drugs Market is segmented by Type, Application, and End-User. Based on the Type, the Congestive Heart Failure Drugs Market is segmented into ACE Inhibitor, Angiotensin Receptor Blocker, Beta Blocker and Diuretics. ACE inhibitor is expected to grow the market by the end of year 2029.This segment held the largest share of 57% in the year 2022. ACE inhibitor prevent an enzyme in the body from produce Angiotensin II, because Angiotensin narrows the blood vessel and create pressure on the wall of artery. This is most common condition occur in patients. ACE inhibitor widely used in heart failure condition. Diuretics segment held the second largest market share in the year 2022. This type of drug helps to dilate the blood vessel in body to supply continuous blood flow and relax the vessel.Congestive Heart Failure Drugs Market, by Type in 2022 (%)
Based on Application, the Congestive Heart Failure Drugs Market is segmented into the Hospital Pharmacies, Retail Pharmacies and Online pharmacies. Hospital Pharmacies held the largest market share of 64% in the year 2022.this segment is also expected to grow further during the forecast period. Because patients always prefer hospital based treatment within the hospital and the stock also easily available in the hospital pharmacy. Retail pharmacy segment is the second large highest segment, held the market share of 45% in the 2022. This segment also expected to grow further during the forecast period.
Congestive Heart Failure Drugs Market, by Application in 2022 (%)
Congestive Heart Failure Drugs Market Regional Insights:
North America expected to dominates the Congestive Heart Failure Drugs Market during the forecast period 2023-2029. North America is expected to grow at a highest share of 26 % in the Congestive Heart Failure Drugs Market by 2029. The rising prevalence of target ailments, rising healthcare spending and public knowledge of treatment is boosting the market globally. For example, in 2022, Amgen Inc. a California-based firm, purchased Dezima Pharma, a Netherlands-based company, in order to expand its cardiovascular medicine portfolio by adding the cholesterol-lowering drug TA-8995. The medication TA-8995 is used to decrease cholesterol levels. The market for congestive heart failure medications in Europe is predicted to expand significantly due to the introduction of new drugs to treat chronic conditions that prevent heart failures. In 2022, Novartis AG launched a medication called Entresto in the UK. Entresto is an angiotensin receptor-neprilysin tobacoid that is used to treat heart failure with a low ejection fraction the percentage of blood that leaves the heart each time it contracts. Market leader’s use a variety of techniques to preserve their dominance in the market, including mergers and acquisitions, product launches, and strategic alliances. In February 2022, Amgen, Cytokinetics, and Servier launched METEORIC-HF, the second phase III clinical trial of omecamtiv mecarbil in heart failure patients. The objective of the report is to present a comprehensive analysis of the Market to the stakeholders in the industry. The past and current status of the industry with the forecasted market size and trends are presented in the report with the analysis of complicated data in simple language. The report covers all the aspects of the industry with a dedicated study of key players that include market leaders, followers, and new entrants. PORTER, PESTEL analysis with the potential impact of micro-economic factors of the market have been presented in the report. External as well as internal factors that are supposed to affect the business positively or negatively have been analyzed, which will give a clear futuristic view of the industry to the decision-makers. The reports also helps in understanding the Market dynamic, structure by analyzing the market segments and project the Market size. Clear representation of competitive analysis of key players by product, price, financial position, product portfolio, growth strategies, and regional presence in the Market make the report investor’s guide.Congestive Heart Failure Drugs Market Scope: Inquire before buying
Global Congestive Heart Failure Drugs Market Report Coverage Details Base Year: 2022 Forecast Period: 2023-2029 Historical Data: 2018 to 2022 Market Size in 2022: US $ 7.62 Bn. Forecast Period 2023 to 2029 CAGR: 12.8% Market Size in 2029: US $ 17.71 Bn. Segments Covered: by Type ACE Inhibitor Angiotensin Receptor Blocker Beta Blocker Diuretics by Application Hospital Pharmacy Retail pharmacy Online Pharmacy Congestive Heart Failure Drugs Market, by Region
North America (United States, Canada and Mexico) Europe (UK, France, Germany, Italy, Spain, Sweden, Austria, Turkey, Russia and Rest of Europe) Asia Pacific (China, India, Japan, South Korea, Australia, ASEAN and Rest of APAC) Middle East and Africa (South Africa, GCC, Egypt, Nigeria and Rest of ME&A) South America (Brazil, Argentina, Columbia and Rest of South America)Congestive Heart Failure Drugs Market, Key Players are
1. Bayer 2. Novartis 3. Merck & Co 4. AstraZeneca 5. GSK 6. Sanofi 7. Bristol-Myers Squibb 8. Mylan 9. Valeant Pharmaceuticals 10. Johnson & Johnson 11. Amgen Inc. 12. AstraZeneca 13. Novartis AG 14. Boehringer Ingelheim International GmbH 15. Johnson & Johnson Services, Inc. 16. Bristol-Myers Squibb Company 17. Merck Sharp & Dohme Corp. 18. Pfizer, Inc.Frequently Asked Questions:
1] What segments are covered in Congestive Heart Failure Drugs Market report? Ans. The segments covered in Market report are based on Type, Application. 2] Which region is expected to hold the highest share in the Market? Ans. North America is expected to hold the highest share in the Market. 3] What is the market size of Market by 2029? Ans. The market size of Market by 2029 is US $ 17.71 Bn. 4] Who are the top key players in the Congestive Heart Failure Drugs Market? Ans. Bayer, Novarti, Merck & Co, AstraZeneca, GSK, Sanofi, Bristol-Myers Squibb, Mylan, Valeant Pharmaceuticals, Johnson & Johnson, Amgen Inc.,AstraZeneca. 5] What was the market size of Congestive Heart Failure Drugs Market in 2022? Ans. The market size of Market in 2022 was US $ 7.62 Bn.
1. Preface 1.1. Market Definition and Key Research Objectives 1.2. Research Highlights 2. Assumptions and Research Methodology 2.1. Report Assumptions 2.2. Abbreviations 2.3. Research Methodology 2.3.1. Secondary Research 2.3.1.1. Secondary data 2.3.1.2. Secondary Sources 2.3.2. Primary Research 2.3.2.1. Data from Primary Sources 2.3.2.2. Breakdown of Primary Sources 3. Executive Summary: Congestive Heart Failure Drugs Market Size, by Market Value (US$ Bn) 3.1. Global Market Segmentation 3.2. Global Market Segmentation Share Analysis, 2022 3.2.1. Global 3.2.2. By Region (North America, Europe, Asia Pacific, South America, Middle East Africa) 3.3. Geographical Snapshot of the Congestive Heart Failure Drugs Market 3.4. Geographical Snapshot of the Congestive Heart Failure Drugs Market , By Manufacturer share 4. Congestive Heart Failure Drugs Market Overview, 2022-2029 4.1. Market Dynamics 4.1.1. Drivers 4.1.1.1. Global 4.1.1.2. By Region (North America, Europe, Asia Pacific, South America, Middle East Africa) 4.1.2. Restraints 4.1.2.1. Global 4.1.2.2. By Region (North America, Europe, Asia Pacific, South America, Middle East Africa) 4.1.3. Opportunities 4.1.3.1. Global 4.1.3.2. By Region (North America, Europe, Asia Pacific, South America, Middle East Africa) 4.1.4. Challenges 4.1.4.1. Global 4.1.4.2. By Region (North America, Europe, Asia Pacific, South America, Middle East Africa) 4.1.5. Industry Trends and Emerging Technologies 4.1.6. Porters Five Forces Analysis 4.1.6.1. Threat of New Entrants 4.1.6.2. Bargaining Power of Buyers/Consumers 4.1.6.3. Bargaining Power of Suppliers 4.1.6.4. Threat of Substitute Products 4.1.6.5. Intensity of Competitive Rivalry 4.1.7. Value Chain Analysis 4.1.8. Technological Roadmap 4.1.9. Regulatory landscape 4.1.10. Impact of the Covid-19 Pandemic on the Congestive Heart Failure Drugs Market 5. Supply Side and Demand Side Indicators 6. Congestive Heart Failure Drugs Market Analysis and Forecast, 2022-2029 6.1. Congestive Heart Failure Drugs Market Size & Y-o-Y Growth Analysis. 7. Congestive Heart Failure Drugs Market Analysis and Forecasts, 2022-2029 7.1. Market Size (Value) Estimates & Forecast By Type, 2022-2029 7.1.1. ACE Inhibitor 7.1.2. Angiotensin Receptor Blocker 7.1.3. Beta Blocker 7.1.4. Diuretics 7.2. Market Size (Value) Estimates & Forecast By Application, 2022-2029 7.2.1. Hospital Pharmacy 7.2.2. Retail pharmacy 7.2.3. Online Pharmacy 8. Congestive Heart Failure Drugs Market Analysis and Forecasts, By Region 8.1. Market Size (Value) Estimates & Forecast By Region, 2022-2029 8.1.1. North America 8.1.2. Europe 8.1.3. Asia-Pacific 8.1.4. Middle East & Africa 8.1.5. South America 9. North America Congestive Heart Failure Drugs Market Analysis and Forecasts, 2022-2029 9.1. Market Size (Value) Estimates & Forecast By Type, 2022-2029 9.1.1. ACE Inhibitor 9.1.2. Angiotensin Receptor Blocker 9.1.3. Beta Blocker 9.1.4. Diuretics 9.1.5. 9.2. Market Size (Value) Estimates & Forecast By Application, 2022-2029 9.2.1. Hospital Pharmacy 9.2.2. Retail pharmacy 9.2.3. Online Pharmacy 10. North America Congestive Heart Failure Drugs Market Analysis and Forecasts, By Country 10.1. Market Size (Value) Estimates & Forecast By Country, 2022-2029 10.1.1. US 10.1.2. Canada 10.1.3. Mexico 11. U.S. Congestive Heart Failure Drugs Market Analysis and Forecasts, 2022-2029 11.1. Market Size (Value) Estimates & Forecast By Type, 2022-2029 11.2. Market Size (Value) Estimates & Forecast By Application, 2022-2029 12. Canada Congestive Heart Failure Drugs Market Analysis and Forecasts, 2022-2029 12.1. Market Size (Value) Estimates & Forecast By Type, 2022-2029 12.2. Market Size (Value) Estimates & Forecast By Application, 2022-2029 13. Mexico Congestive Heart Failure Drugs Market Analysis and Forecasts, 2022-2029 13.1. Market Size (Value) Estimates & Forecast By Type, 2022-2029 13.2. Market Size (Value) Estimates & Forecast By Application, 2022-2029 14. Europe Congestive Heart Failure Drugs Market Analysis and Forecasts, 2022-2029 14.1. Market Size (Value) Estimates & Forecast By Type, 2022-2029 14.2. Market Size (Value) Estimates & Forecast By Application, 2022-2029 15. Europe Congestive Heart Failure Drugs Market Analysis and Forecasts, By Country 15.1. Market Size (Value) Estimates & Forecast By Country, 2022-2029 15.1.1. U.K 15.1.2. France 15.1.3. Germany 15.1.4. Italy 15.1.5. Spain 15.1.6. Sweden 15.1.7. CIS Countries 15.1.8. Rest of Europe 16. U.K. Congestive Heart Failure Drugs Market Analysis and Forecasts, 2022-2029 16.1. Market Size (Value) Estimates & Forecast By Type, 2022-2029 16.2. Market Size (Value) Estimates & Forecast By Application, 2022-2029 17. France Congestive Heart Failure Drugs Market Analysis and Forecasts, 2022-2029 17.1. Market Size (Value) Estimates & Forecast By Type, 2022-2029 17.2. Market Size (Value) Estimates & Forecast By Application, 2022-2029 18. Germany Congestive Heart Failure Drugs Market Analysis and Forecasts, 2022-2029 18.1. Market Size (Value) Estimates & Forecast By Type, 2022-2029 18.2. Market Size (Value) Estimates & Forecast By Application, 2022-2029 19. Italy Congestive Heart Failure Drugs Market Analysis and Forecasts, 2022-2029 19.1. Market Size (Value) Estimates & Forecast By Type, 2022-2029 19.2. Market Size (Value) Estimates & Forecast By Application, 2022-2029 20. Spain Congestive Heart Failure Drugs Market Analysis and Forecasts, 2022-2029 20.1. Market Size (Value) Estimates & Forecast By Type, 2022-2029 20.2. Market Size (Value) Estimates & Forecast By Application, 2022-2029 21. Sweden Congestive Heart Failure Drugs Market Analysis and Forecasts, 2022-2029 21.1. Market Size (Value) Estimates & Forecast By Type, 2022-2029 21.2. Market Size (Value) Estimates & Forecast By Application, 2022-2029 22. CIS Countries Congestive Heart Failure Drugs Market Analysis and Forecasts, 2022-2029 22.1. Market Size (Value) Estimates & Forecast By Type, 2022-2029 22.2. Market Size (Value) Estimates & Forecast By Application, 2022-2029 23. Rest of Europe Congestive Heart Failure Drugs Market Analysis and Forecasts, 2022-2029 23.1. Market Size (Value) Estimates & Forecast By Type, 2022-2029 23.2. Market Size (Value) Estimates & Forecast By Application, 2022-2029 24. Asia Pacific Congestive Heart Failure Drugs Market Analysis and Forecasts, 2022-2029 24.1. Market Size (Value) Estimates & Forecast By Type, 2022-2029 24.2. Market Size (Value) Estimates & Forecast By Application, 2022-2029 25. Asia Pacific Congestive Heart Failure Drugs Market Analysis and Forecasts, by Country 25.1. Market Size (Value) Estimates &Forecast By Country, 2022-2029 25.1.1. China 25.1.2. India 25.1.3. Japan 25.1.4. South Korea 25.1.5. Australia 25.1.6. ASEAN 25.1.7. Rest of Asia Pacific 26. China Congestive Heart Failure Drugs Market Analysis and Forecasts, 2022-2029 26.1. Market Size (Value) Estimates & Forecast By Type, 2022-2029 26.2. Market Size (Value) Estimates & Forecast By Application, 2022-2029 27. India Congestive Heart Failure Drugs Market Analysis and Forecasts, 2022-2029 27.1. Market Size (Value) Estimates & Forecast By Type, 2022-2029 27.2. Market Size (Value) Estimates & Forecast By Application, 2022-2029 28. Japan Congestive Heart Failure Drugs Market Analysis and Forecasts, 2022-2029 28.1. Market Size (Value) Estimates & Forecast By Type, 2022-2029 28.2. Market Size (Value) Estimates & Forecast By Application, 2022-2029 29. South Korea Congestive Heart Failure Drugs Market Analysis and Forecasts, 2022-2029 29.1. Market Size (Value) Estimates & Forecast By Type, 2022-2029 29.2. Market Size (Value) Estimates & Forecast By Application, 2022-2029 29.3. Market Size (Value) Estimates & Forecast By End-User, 2022-2029 30. Australia Congestive Heart Failure Drugs Market Analysis and Forecasts, 2022-2029 30.1. Market Size (Value) Estimates & Forecast By Type, 2022-2029 30.2. Market Size (Value) Estimates & Forecast By Application, 2022-2029 31. ASEAN Congestive Heart Failure Drugs Market Analysis and Forecasts, 2022-2029 31.1. Market Size (Value) Estimates & Forecast By Type, 2022-2029 31.2. Market Size (Value) Estimates & Forecast By Application, 2022-2029 32. Analysis and Forecasts, 2022-2029 32.1. Market Size (Value) Estimates & Forecast By Type, 2022-2029 32.2. Market Size (Value) Estimates & Forecast By Application, 2022-2029 33. Middle East Africa Congestive Heart Failure Drugs Market Analysis and Forecasts, 2022-2029 33.1. Market Size (Value) Estimates & Forecast By Type, 2022-2029 33.2. Market Size (Value) Estimates & Forecast By Application, 2022-2029 34. Middle East Africa Congestive Heart Failure Drugs Market Analysis and Forecasts, by Country 34.1. Market Size (Value) Estimates & Forecast by Country, 2022-2029 34.1.1. South Africa 34.1.2. GCC Countries 34.1.3. Egypt 34.1.4. Nigeria 34.1.5. Rest of ME&A 35. South Africa Congestive Heart Failure Drugs Market Analysis and Forecasts, 2022-2029 35.1. Market Size (Value) Estimates & Forecast By Type, 2022-2029 35.2. Market Size (Value) Estimates & Forecast By Application, 2022-2029 36. GCC Countries Congestive Heart Failure Drugs Market Analysis and Forecasts, 2022-2029 36.1. Market Size (Value) Estimates & Forecast By Type, 2022-2029 36.2. Market Size (Value) Estimates & Forecast By Application, 2022-2029 37. Egypt Congestive Heart Failure Drugs Market Analysis and Forecasts, 2022-2029 37.1. Market Size (Value) Estimates & Forecast By Type, 2022-2029 37.2. Market Size (Value) Estimates & Forecast By Application, 2022-2029 38. Nigeria Congestive Heart Failure Drugs Market Analysis and Forecasts, 2022-2029 38.1. Market Size (Value) Estimates & Forecast By Type, 2022-2029 38.2. Market Size (Value) Estimates & Forecast By Application, 2022-2029 38.3. Market Size (Value) Estimates & Forecast By End-User, 2022-2029 39. Rest of ME&A Congestive Heart Failure Drugs Market Analysis and Forecasts, 2022-2029 39.1. Market Size (Value) Estimates & Forecast By Type, 2022-2029 39.2. Market Size (Value) Estimates & Forecast By Application, 2022-2029 40. South America Congestive Heart Failure Drugs Market Analysis and Forecasts, 2022-2029 40.1. Market Size (Value) Estimates & Forecast By Type, 2022-2029 40.2. Market Size (Value) Estimates & Forecast By Application, 2022-2029 41. South America Congestive Heart Failure Drugs Market Analysis and Forecasts, by Country 41.1. Market Size (Value) Estimates & Forecast by Country, 2022-2029 41.1.1. Brazil 41.1.2. Argentina 41.1.3. Rest of South America 42. Brazil Congestive Heart Failure Drugs Market Analysis and Forecasts, 2022-2029 42.1. Market Size (Value) Estimates & Forecast By Type, 2022-2029 42.2. Market Size (Value) Estimates & Forecast By Application, 2022-2029 43. Argentina Congestive Heart Failure Drugs Market Analysis and Forecasts, 2022-2029 43.1. Market Size (Value) Estimates & Forecast By Type, 2022-2029 43.2. Market Size (Value) Estimates & Forecast By Application, 2022-2029 44. Rest of South America Congestive Heart Failure Drugs Market Analysis and Forecasts, 2022-2029 44.1. Market Size (Value) Estimates & Forecast By Type, 2022-2029 44.2. Market Size (Value) Estimates & Forecast By Application, 2022-2029 45. Competitive Landscape 45.1. Geographic Footprint of Major Players in the Congestive Heart Failure Drugs Market 45.2. Competition Matrix 45.2.1. Competitive Benchmarking of Key Players By Price, Presence, Market Share, Applications and R&D Investment 45.2.2. New Product Launches and Product Enhancements 45.2.3. Market Consolidation 45.2.3.1. M&A by Regions, Investment and Verticals 45.2.3.2. M&A, Forward Integration and Backward Integration 45.2.3.3. Partnership, Joint Ventures and Strategic Alliances/ Sales Agreements 45.3. Company Profile : Key Players 45.3.1. Bayer 45.3.1.1. Company Overview 45.3.1.2. Financial Overview 45.3.1.3. Geographic Footprint 45.3.1.4. Product Portfolio 45.3.1.5. Business Strategy 45.3.1.6. Recent Developments 45.3.2. Novartis 45.3.3. Merck & Co 45.3.4. AstraZeneca 45.3.5. GSK 45.3.6. Sanofi 45.3.7. Bristol-Myers Squibb 45.3.8. Mylan 45.3.9. Valeant Pharmaceuticals 45.3.10. Johnson & Johnson 45.3.11. Amgen Inc. 45.3.12. AstraZeneca 45.3.13. Novartis AG 45.3.14. Boehringer Ingelheim International GmbH 45.3.15. Johnson & Johnson Services, Inc. 45.3.16. Bristol-Myers Squibb Company 45.3.17. Merck Sharp & Dohme Corp. 45.3.18. Pfizer, Inc. 46. Primary Key Insights